Which physiological response will the nurse expect to assess in patients taking hydralazine (Apresoline), which is a vasodilator medication?

Choice A reason: Infection in the blood is not empyema. It is sepsis, which is a life-threatening condition that occurs when the body's response to infection causes tissue damage, organ failure, or death.

Choice B reason: Infection in the pleural space is empyema. It is a collection of pus in the space between the lungs and the chest wall, usually caused by a bacterial infection that spreads from the lungs or the chest cavity.

Choice C reason: Exudative bronchitis is not empyema. It is a type of bronchitis that involves inflammation and excess mucus production in the bronchi, the airways that carry air to the lungs.

Choice D reason: Infection localized in the lung is not empyema. It is pneumonia, which is an inflammation of the lung tissue, usually caused by a viral or bacterial infection that affects the air sacs or the interstitial tissue.

Choice A reason: This is not a correct statement. LABAs stand for long-acting beta2-agonists, which are a class of medications that relax the smooth muscles of the airways and improve the airflow in patients with asthma or COPD. However, LABAs do not reduce the risk of asthma-related deaths, and may even increase it if used alone without an inhaled glucocorticoid, which is a type of anti-inflammatory medication.

Choice B reason: This is not a correct statement. LABAs cannot be used on an as-needed basis to treat symptoms, as they have a slow onset of action and a long duration of effect. LABAs are meant to be used as a maintenance therapy to prevent asthma exacerbations, not to relieve acute symptoms. For quick relief of symptoms, patients should use a short-acting beta2-agonist, such as albuterol or salbutamol.

Choice C reason: This is not a correct statement. LABAs are not safer than short-acting beta2 agonists, as they have similar side effects, such as tachycardia, tremors, and hypokalemia. LABAs also have a black box warning that they may increase the risk of asthma-related deaths if used without an inhaled glucocorticoid.

Choice D reason: This is the correct statement. LABAs should be combined with an inhaled glucocorticoid, as this combination has been shown to improve the asthma control, reduce the frequency and severity of exacerbations, and decrease the inflammation and airway hyperresponsiveness. The inhaled glucocorticoid also reduces the risk of adverse effects and mortality associated with LABAs.